President & CEO
EA Pharma Co., Ltd. is a gastrointestinal specialty pharma, established in April 2016 through the integration of the respective gastrointestinal business units of the Eisai Group and the Ajinomoto Group.
EA Pharma Co., Ltd. is an innovation-driven company, combining the accumulated experience and data (‘knowledge’) of the two Groups in drug discovery, clinical development, pharmacovigilance, manufacturing and marketing in the disease areas of the upper/lower gastrointestinal tract, the liver and the pancreas.
The environment surrounding the pharmaceutical industry is currently changing at an unprecedented rate. We aim to have a ‘hard’ core and ‘flexible’ adaptableness so that we can take a leading role in these changes. As a human health care (hhc) company specializing in the gastrointestinal disease area, we are committed to providing a stable supply of high-quality pharmaceuticals.
There exist a number of unmet medical needs in the gastrointestinal disease area. EA Pharma Co., Ltd. stays close to patients and their families, to identify their real needs and provide wide-ranging solutions to meet these needs. This is where we can make the greatest contribution in healthcare.
We ask all of our stakeholders for their continued support going forward.